Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback